Gynecologic Cancer (HIPEC) 12-275

January 03, 2017

Sponsor: Memorial Sloan Kettering Cancer Center

Number: (HIPEC) 12-275
This is a Phase II randomized clinical trial meant to determine if performing a complex surgical procedure called hyperthermic intraperitoneal chemotherapy (HIPEC), along with standard post-operative surgery, is more effective in fighting gynecologic cancer than standard post-operative chemotherapy alone.

Who’s eligible: Patients who have had a first recurrence of ovarian, fallopian tube, or primary peritoneal cancer that initially responded to platinum-based therapy and which returned more than 6 and less than 30 months after completing that therapy.

Patients must be candidates for a second surgery to remove cancerous tissue in the abdomen.

The cancerous tissue remaining after the second surgery should be less than 5mm in size.

Patients may not have had prior chemotherapy for recurrent disease, nor any previous radiation therapy to the pelvis.

This study is open to patients age 21 and older.

Available at: Hartford Hospital.

Cancer Clinical Research Office